Method for producing the crystalline form of modification a of calcobutrol
A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and then with a calcium salt the calcium complex is produced in high purity. During the crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of the modification A of the compound of the formula (I) is used in the production of Gadovist.
1. A compound of formula (I) in a crystalline form of modification A
wherein an x-ray powder diffraction diagram of the compound shows peak maxima of a 2 theta angle at 7.6°, 9.1°, 11.1°, 11.3°, 11.9° and 12.3°.
2. A compound of formula (I) in a crystalline form of modification A
wherein the compound is a monohydrate with 2.0-2.5 weight % ethanol.
3. A compound of claim 2 having the formula (I) in the crystalline form of modification A
wherein an x-ray powder diffraction diagram of the compound shows peak maxima of a 2 theta angle at 7.6°, 9.1°, 11.1°, 11.3°, 11.9° and 12.3°.
4. A compound of formula (I) in a crystalline form of modification A produced by a method comprising:
treating a solution of a dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid ligand to an acidic ion exchanger to bind the dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid ligand to an acidic ion exchange column;
eluting the acidic ion exchange column having the bound dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid ligand with an aqueous basic solution to give an eluted solution of the dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid ligand;
complexing the eluted solution of the dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid ligand with Ca 2+ ;
adjusting a stoichiometric ratio of the dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid ligand and Ca 2+ to 1:1 to afford a calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid;
crystallizing the calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid from an aqueous ethanol solution with a water content of from 9 to 11 weight % of water to give a crystallized calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid; and
isolating and drying the crystallized calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid to afford the compound of formula (I) in the crystalline form of modification A,
wherein an x-ray powder diffraction diagram of the compound shows peak maxima of a 2 theta angle at 7.6°, 9.1°, 11.1°, 11.3°, 11.9° and 12.3°.
5. The compound of the formula (I) of claim 1 , wherein the compound has a purity of greater than or equal to 99.0%.
6. The compound of the formula (I) of claim 1 , wherein the compound has a purity of greater than or equal to 99.7%.
7. A galenical formulation of Gadobutrol, the formulation comprising:
Gadobutrol dissolved in a suitable pharmaceutical solvent; and
a calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid in a crystalline form of modification A dissolved in the suitable pharmaceutical solvent,
wherein an x-ray powder diffraction diagram of the crystalline form of the modification A of the calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid shows peak maxima of a 2 theta angle at 7.6°, 9.1°, 11.1°, 11.3°, 11.9° and 12.3°.
8. The galenical formulation of Gadobutrol of claim 7 , wherein the calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid has a purity of greater than or equal to 99.0%.